| Revenue growth | FY26 revenue declined 12% YoY to ₹1,054.9 Cr. |
|---|---|
| Margins | EBITDA margin contracted to 34.8% from 42.2% YoY. |
| Order book | Strong customer acquisition pipeline for FY27. |
| Demand visibility | Staggered procurement patterns in US/EU impacting short-term visibility. |
| Management confidence | High for FY27 recovery despite a challenging FY26. |
Growth
FY26 Revenue fell 12% to ₹1,054.9 Cr. EBITDA dropped 27% to ₹367.4 Cr; PAT declined 30% to ₹259.2 Cr.
Outlook
Management expects strong outperformance in FY27 driven by product expansion, customer diversification, and new injectable/soft gel facilities.
Risks
US tariff uncertainty, US-Iran conflict affecting Middle East tenders, and delayed EU regulatory confirmations impacted performance.
Earnings Call filed with BSE, NSE: CONCORDBIO. Summary written with AI assistance from the document.
Concord Biotech Ltd: key numbers
- Share price
- ₹1,453.60
- Market cap
- ₹15,207 Cr
- Revenue (annual)
- ₹1,055 Cr
- Net profit (annual)
- ₹260.9 Cr
- P/E (TTM)
- 55.2×Sector 50.4×
- Promoter holding
- 44.08%+0.00% QoQ
- FII holding
- 7.53%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Concord Biotech Ltd
All →Concord Biotech Bonus Issue
Concord Biotech's board recommended a 1:1 bonus share issue from free reserves. Shareholders will consider this proposal at an upcoming postal ballot on October 24, 2026.
Concord Biotech Bonus Issue
Concord Biotech approved a 1:1 bonus issue of 10.46 crore equity shares. The board also increased the company's authorized share capital to Rs. 22 Crore.
- Value
- ₹10.46 Cr
Concord Biotech Board Meeting Date
Concord Biotech Ltd announced a board meeting for September 23, 2026, to consider a proposal for the declaration of bonus equity shares.
Concord Biotech Business Update
Concord Biotech disclosed a successful USFDA inspection at its Valthera facility with one minor non-GMP observation. No material impact on operations or existing supplies is expected.
Concord Biotech Earnings Call Transcript: Key Takeaways
Concord reports a strong 26% revenue recovery in Q1FY27, pivoting from a challenging FY26 despite previous procurement delays.
Concord Biotech Investor Presentation: Key Takeaways
Concord Biotech reported strong Q1FY27 consolidated performance with 26% revenue growth and 31% PAT growth, driven by a 46% surge in exports and expanding market share in niche fermentation APIs.